




Class:SHHa Sample:MD 24 Prob(SHHa) = 1



Class:SHHa Sample:MD 149 Prob(SHHa) = 1



Class:SHHb Sample:MD 130.1 Prob(SHHb) = 0.9




Class:SHHa Sample:MD_97 Prob(SHHa) = 1


Class:SHHb Sample:MD_97 Prob(SHHb) = 7.28e-

Class:SHHa Sample:MD_25 Prob(SHHa) = 1


Cumulative log odds: 390



Cumulative log odds: -390



Cumulative log odds: 210




Class:SHHb Sample:MD_25 Prob(SHHb) = 1.36e-


Class:SHHa Sample:MD_135 Prob(SHHa) = 1

Class:SHHb Sample:MD_135 Prob(SHHb) = 1.73e-


Cumulative log odds: -210




Cumulative log odds: 57




Cumulative log odds: -57



Class:SHHa Sample:MD_102 Prob(SHHa) = 1



Class:SHHa Sample:MD_139 Prob(SHHa) = 1.56e-



Class:SHHa Sample:MD 182 Prob(SHHa) = 1



Class:SHHb Sample:MD 179 Prob(SHHb) = 3.61e




Class:SHHa Sample:MD_181 Prob(SHHa) = 1

Class:SHHb Sample:MD_181 Prob(SHHb) = 2.07e



Class:SHHa Sample:MD_89 Prob(SHHa) = 1

Relative log odds: 200





Evidence (posterior log odds)

Cumulative log odds: -200



Evidence (posterior log odds)

Cumulative log odds: 290




Evidence (posterior log odds)

Class:SHHb Sample:MD_89 Prob(SHHb) = 6.01e-

Class:SHHa Sample:MD_236 Prob(SHHa) = 1


Class:SHHb Sample:MD_236 Prob(SHHb) = 8.96e-

Relative log odds: -290





Evidence (posterior log odds)

Cumulative log odds: 140




Evidence (posterior log odds)

Cumulative log odds: -140



Evidence (posterior log odds)


Class:SHHa Sample:MD 151 Prob(SHHa) = 1




Class:SHHb Sample:MD_241 Prob(SHHb) = 4.09e-



Class:SHHa Sample:MD 257 Prob(SHHa) = 1



Class:SHHb Sample:MD_86.1 Prob(SHHb) = 2.97e



Class:SHHa Sample:MD_109 Prob(SHHa) = 1

Class:SHHb Sample:MD_109 Prob(SHHb) = 2.44e

Class:SHHa Sample:MD_187 Prob(SHHa) = 1

Relative log odds: 150



Evidence (posterior log odds)

Cumulative log odds: -150



Evidence (posterior log odds)

Cumulative log odds: 190



Evidence (posterior log odds)

Class:SHHb Sample:MD_187 Prob(SHHb) = 1.14e

Class:SHHa Sample:MD_94 Prob(SHHa) = 1


Class:SHHb Sample:MD_94 Prob(SHHb) = 4.14e

Relative log odds: -190




Evidence (posterior log odds)

Cumulative log odds: 170



Evidence (posterior log odds)

Cumulative log odds: -170



Evidence (posterior log odds)

Class:SHHa Sample:MD_126 Prob(SHHa) = 1

Class:SHHb Sample:MD_126 Prob(SHHb) = 1.57e-


Class:SHHa Sample:MD_270 Prob(SHHa) = 1.4e-

Cumulative log odds: 330

PKR PATHWAY: 1.1
PI3K/AKT/MTOR SIGNALING PATHWAY: 1.1
AQUAPORINS: 1.6
GPCR PATHWAY: 0.77
CK1 PATHWAY: 0.77
HYPOTHALAMUS DN: 1.3
MEMBRANE TRANSPORT FROM THE PLASMA MEMBRANE: 0.93
PC12 DIFFERENTIATION PATHWAY IN PC12 CELLS: 0.26
TRANSFORMER-1 SIGNAL TRANSDUCTION: 0.53
AND SUFU DN: 0.63
MELLMAN TUT1 TARGETS: 1.3
ERBB2 CDC25A TUMORIGENESIS BY ERBB2 AND TP53: 0.33
SANTINIPK/ERBB2 TARGETS OF TP53 AND TP73: 0.73
INCIPIT/ALZHEIMERS DISEASE: 0.33
GLUCURONATE INTERCONVERSIONS: 0.33
DISEASE: 0.73
CD1 AND CD2: 0.56
GOZG1 ESR1 TARGETS: 0.46
SE AND XPC: 0.44
ST_CANCER: 0.56

Cumulative log odds: -330


PKR PATHWAY: 1.1
PI3K/AKT/MTOR SIGNALING PATHWAY: 1.1
AQUAPORINS: 1.6
GPCR PATHWAY: 0.77
CK1 PATHWAY: 0.77
HYPOTHALAMUS DN: 1.3
MEMBRANE TRANSPORT FROM THE PLASMA MEMBRANE: 0.93
PC12 DIFFERENTIATION PATHWAY IN PC12 CELLS: 0.26
TRANSFORMER-1 SIGNAL TRANSDUCTION: 0.53
AND SUFU DN: 0.63
MELLMAN TUT1 TARGETS: 1.3
ERBB2 CDC25A TUMORIGENESIS BY ERBB2 AND TP53: 0.33
SANTINIPK/ERBB2 TARGETS OF TP53 AND TP73: 0.73
INCIPIT/ALZHEIMERS DISEASE: 0.33
GLUCURONATE INTERCONVERSIONS: 0.33
DISEASE: 0.73
CD1 AND CD2: 0.56
GOZG1 ESR1 TARGETS: 0.46
SE AND XPC: 0.44
ST_CANCER: 0.56



Evidence (posterior log odds)

Cumulative log odds: -180

PKR PATHWAY: 1.2
PI3K/AKT/MTOR SIGNALING PATHWAY: 1.2
AQUAPORINS: 0.32
GPCR PATHWAY: 0.78
CK1 PATHWAY: 1.78
HYPOTHALAMUS DN: 1.75
MEMBRANE TRANSPORT FROM THE PLASMA MEMBRANE: 0.93
PC12 DIFFERENTIATION PATHWAY IN PC12 CELLS: 0.26
TRANSFORMER-1 SIGNAL TRANSDUCTION: 0.53
AND SUFU DN: 2.1
MELLMAN TUT1 TARGETS: 1.3
ERBB2 CDC25A TUMORIGENESIS BY ERBB2 AND TP53: 0.33
SANTINIPK/ERBB2 TARGETS OF TP53 AND TP73: 0.73
INCIPIT/ALZHEIMERS DISEASE: 0.33
GLUCURONATE INTERCONVERSIONS: 0.33
DISEASE: 0.73
CD1 AND CD2: 0.56
GOZG1 ESR1 TARGETS: 0.46
SE AND XPC: 0.44
ST_CANCER: 0.56



Evidence (posterior log odds)

Class:SHHb Sample:MD_270 Prob(SHHb) = 1

Class:SHHa Sample:MD_153 Prob(SHHa) = 1


Class:SHHb Sample:MD_153 Prob(SHHb) = 9.999999999

Cumulative log odds: 180

PKR PATHWAY: 1.2
PI3K/AKT/MTOR SIGNALING PATHWAY: 1.2
AQUAPORINS: 0.41
GPCR PATHWAY: 0.78
CK1 PATHWAY: 1.78
HYPOTHALAMUS DN: 1.75
MEMBRANE TRANSPORT FROM THE PLASMA MEMBRANE: 0.93
PC12 DIFFERENTIATION PATHWAY IN PC12 CELLS: 0.26
TRANSFORMER-1 SIGNAL TRANSDUCTION: 0.53
AND SUFU DN: 0.63
MELLMAN TUT1 TARGETS: 1.3
ERBB2 CDC25A TUMORIGENESIS BY ERBB2 AND TP53: 0.33
SANTINIPK/ERBB2 TARGETS OF TP53 AND TP73: 0.73
INCIPIT/ALZHEIMERS DISEASE: 0.33
GLUCURONATE INTERCONVERSIONS: 0.33
DISEASE: 0.73
CD1 AND CD2: 0.56
GOZG1 ESR1 TARGETS: 0.46
SE AND XPC: 0.44
ST_CANCER: 0.56

Cumulative log odds: 550


PKR PATHWAY: 1.2
PI3K/AKT/MTOR SIGNALING PATHWAY: 1.2
AQUAPORINS: 0.41
GPCR PATHWAY: 0.78
CK1 PATHWAY: 1.78
HYPOTHALAMUS DN: 1.75
MEMBRANE TRANSPORT FROM THE PLASMA MEMBRANE: 0.93
PC12 DIFFERENTIATION PATHWAY IN PC12 CELLS: 0.26
TRANSFORMER-1 SIGNAL TRANSDUCTION: 0.53
AND SUFU DN: 0.63
MELLMAN TUT1 TARGETS: 1.3
ERBB2 CDC25A TUMORIGENESIS BY ERBB2 AND TP53: 0.33
SANTINIPK/ERBB2 TARGETS OF TP53 AND TP73: 0.73
INCIPIT/ALZHEIMERS DISEASE: 0.33
GLUCURONATE INTERCONVERSIONS: 0.33
DISEASE: 0.73
CD1 AND CD2: 0.56
GOZG1 ESR1 TARGETS: 0.46
SE AND XPC: 0.44
ST_CANCER: 0.56



Evidence (posterior log odds)

Cumulative log odds: -550

PKR PATHWAY: 1.2
PI3K/AKT/MTOR SIGNALING PATHWAY: 1.2
AQUAPORINS: 0.41
GPCR PATHWAY: 0.78
CK1 PATHWAY: 1.78
HYPOTHALAMUS DN: 1.75
MEMBRANE TRANSPORT FROM THE PLASMA MEMBRANE: 0.93
PC12 DIFFERENTIATION PATHWAY IN PC12 CELLS: 0.26
TRANSFORMER-1 SIGNAL TRANSDUCTION: 0.53
AND SUFU DN: 0.63
MELLMAN TUT1 TARGETS: 1.3
ERBB2 CDC25A TUMORIGENESIS BY ERBB2 AND TP53: 0.33
SANTINIPK/ERBB2 TARGETS OF TP53 AND TP73: 0.73
INCIPIT/ALZHEIMERS DISEASE: 0.33
GLUCURONATE INTERCONVERSIONS: 0.33
DISEASE: 0.73
CD1 AND CD2: 0.56
GOZG1 ESR1 TARGETS: 0.46
SE AND XPC: 0.44
ST_CANCER: 0.56




Evidence (posterior log odds)

Class:SHHa Sample:MD_237 Prob(SHHa) = 1

Class:SHHb Sample:MD_237 Prob(SHHb) = 9.22e

Class:SHHa Sample:MD_178 Prob(SHHa) = 1.26e

Cumulative log odds: 180




Evidence (posterior log odds)

Cumulative log odds: -180



Evidence (posterior log odds)

Cumulative log odds: -110



Evidence (posterior log odds)

Class:SHHb Sample:MD_178 Prob(SHHb) = 1

Class:SHHa Sample:MD_50 Prob(SHHa) = 1

Class:SHHb Sample:MD_50 Prob(SHHb) = 1.44e

Cumulative log odds: 110




Evidence (posterior log odds)

Cumulative log odds: 62



Evidence (posterior log odds)

Cumulative log odds: -62



Evidence (posterior log odds)


Class:SHHa Sample:MD 2.1 Prob(SHHa) = 1



Class:SHHb Sample:MD 32 Prob(SHHb) = 1.36e-



Class:SHHa Sample:MD 43 Prob(SHHa) = 1



Class:SHHb Sample:MD 137.1 Prob(SHHb) = 1




Class:SHHa Sample:MD_91 Prob(SHHa) = 1

Class:SHHb Sample:MD_91 Prob(SHHb) = 9.15e-


Class:SHHa Sample:MD_42 Prob(SHHa) = 1

Cumulative log odds: 400

KR PATHWAY: -2.1
G PATHWAY: -0.33
CR PATHWAY: 0.33
CK1 PATHWAY: 0.2
ALAMUS DN: 0.26
MNCBRANER KABARDOMEINGH ASSAMAMMNCBRANER K4FROM THE PLASMA MEMBRANE: 0.67
PC12 DIFFERENTIATION PATHWAY IN PC12 CELLS: 1.5
SIGNAL TRANSDUCTION DOWNSTREAM SIGNAL TRANSDUCTION: 1
SUFU DN: 0.96
T1 TARGETS: 0.66
B2 CDC25A HOMORIGENESIS BY ERBB2 CDC25A HOMORIGENESIS BY ERBB2 CDC25A: 0.67
3 ANDAN INVERSED TARGETS OF TP53 ANDAN INVERSED TARGETS OF TP53 AND TP73: 0.83
F INCIPITANOCK ALZHEIMERS DISEASE INCIPITANOCK ALZHEIMERS DISEASE INCIPITANT: 0.33
NOSIONS: G12CURONATE INTERCONVERSIONS: 0.33
RS DISEASE: 1.3
1 ANDZHEAN MULTIPLE MYELOMA CD1 ANDZHEAN MULTIPLE MYELOMA CD1 AND CD2: 0.33
1 TARGETS: 0.27
SE AND XPC: 0.51
AST_CANCER: 0.15




PID TRKR PATHWAY: -2.1
G PATHWAY: -0.33
CR PATHWAY: 0.33
CK1 PATHWAY: 0.2
ALAMUS DN: 0.26
MNCBRANER K4FROM THE PLASMA MEMBRANE: 0.67
PC12 DIFFERENTIATION PATHWAY IN PC12 CELLS: 1.5
SIGNAL TRANSDUCTION DOWNSTREAM SIGNAL TRANSDUCTION: 1
SUFU DN: 0.96
T1 TARGETS: 0.66
B2 CDC25A HOMORIGENESIS BY ERBB2 CDC25A HOMORIGENESIS BY ERBB2 CDC25A: 0.67
3 ANDAN INVERSED TARGETS OF TP53 ANDAN INVERSED TARGETS OF TP53 AND TP73: 0.83
F INCIPITANOCK ALZHEIMERS DISEASE INCIPITANOCK ALZHEIMERS DISEASE INCIPITANT: 0.33
NOSIONS: G12CURONATE INTERCONVERSIONS: 0.33
RS DISEASE: 1.3
1 ANDZHEAN MULTIPLE MYELOMA CD1 ANDZHEAN MULTIPLE MYELOMA CD1 AND CD2: 0.33
1 TARGETS: 0.27
SE AND XPC: 0.51
AST_CANCER: 0.15



Cumulative log odds: 53

PID TRKR PATHWAY: 0.22
G PATHWAY: 0.33
CR PATHWAY: 1.3
CK1 PATHWAY: 0.47
ALAMUS DN: 0.26
MNCBRANER K4FROM THE PLASMA MEMBRANE: 0.67
PC12 DIFFERENTIATION PATHWAY IN PC12 CELLS: 1.5
SIGNAL TRANSDUCTION DOWNSTREAM SIGNAL TRANSDUCTION: 1
SUFU DN: 0.96
T1 TARGETS: 0.66
B2 CDC25A HOMORIGENESIS BY ERBB2 CDC25A HOMORIGENESIS BY ERBB2 CDC25A: 0.67
3 ANDAN INVERSED TARGETS OF TP53 ANDAN INVERSED TARGETS OF TP53 AND TP73: 0.83
F INCIPITANOCK ALZHEIMERS DISEASE INCIPITANOCK ALZHEIMERS DISEASE INCIPITANT: 0.33
NOSIONS: G12CURONATE INTERCONVERSIONS: 0.33
RS DISEASE: 1.3
1 ANDZHEAN MULTIPLE MYELOMA CD1 ANDZHEAN MULTIPLE MYELOMA CD1 AND CD2: 0.33
1 TARGETS: 0.27
SE AND XPC: 0.51
AST_CANCER: 0.15




Class:SHHb Sample:MD_42 Prob(SHHb) = 1.53e-

Class:SHHa Sample:MD_37 Prob(SHHa) = 1.61e-

Class:SHHb Sample:MD_37 Prob(SHHb) = 1


Cumulative log odds: -53

KR PATHWAY: 0.22
G PATHWAY: -0.33
CR PATHWAY: 0.33
CK1 PATHWAY: 0.47
ALAMUS DN: 0.26
MNCBRANER K4FROM THE PLASMA MEMBRANE: 0.67
PC12 DIFFERENTIATION PATHWAY IN PC12 CELLS: 1.5
SIGNAL TRANSDUCTION DOWNSTREAM SIGNAL TRANSDUCTION: 1
SUFU DN: 0.96
T1 TARGETS: 0.66
B2 CDC25A HOMORIGENESIS BY ERBB2 CDC25A HOMORIGENESIS BY ERBB2 CDC25A: 0.67
3 ANDAN INVERSED TARGETS OF TP53 ANDAN INVERSED TARGETS OF TP53 AND TP73: 0.83
F INCIPITANOCK ALZHEIMERS DISEASE INCIPITANOCK ALZHEIMERS DISEASE INCIPITANT: 0.33
NOSIONS: G12CURONATE INTERCONVERSIONS: 0.33
RS DISEASE: 1.3
1 ANDZHEAN MULTIPLE MYELOMA CD1 ANDZHEAN MULTIPLE MYELOMA CD1 AND CD2: 0.33
1 TARGETS: 0.27
SE AND XPC: 0.51
AST_CANCER: 0.15




Cumulative log odds: -20

PID TRKR PATHWAY: 0.64
G PATHWAY: -0.33
CR PATHWAY: 0.33
CK1 PATHWAY: 0.57
ALAMUS DN: 0.26
MNCBRANER K4FROM THE PLASMA MEMBRANE: 0.67
PC12 DIFFERENTIATION PATHWAY IN PC12 CELLS: 1.5
SIGNAL TRANSDUCTION DOWNSTREAM SIGNAL TRANSDUCTION: 1
SUFU DN: 0.96
T1 TARGETS: 0.66
B2 CDC25A HOMORIGENESIS BY ERBB2 CDC25A HOMORIGENESIS BY ERBB2 CDC25A: 0.67
3 ANDAN INVERSED TARGETS OF TP53 ANDAN INVERSED TARGETS OF TP53 AND TP73: 0.83
F INCIPITANOCK ALZHEIMERS DISEASE INCIPITANOCK ALZHEIMERS DISEASE INCIPITANT: 0.33
NOSIONS: G12CURONATE INTERCONVERSIONS: 0.33
RS DISEASE: 1.3
1 ANDZHEAN MULTIPLE MYELOMA CD1 ANDZHEAN MULTIPLE MYELOMA CD1 AND CD2: 0.33
1 TARGETS: 0.27
SE AND XPC: 0.51
AST_CANCER: 0.15



Cumulative log odds: 20

PID TRKR PATHWAY: 0.64
G PATHWAY: -0.33
CR PATHWAY: 0.33
CK1 PATHWAY: 0.57
ALAMUS DN: 0.26
MNCBRANER K4FROM THE PLASMA MEMBRANE: 0.67
PC12 DIFFERENTIATION PATHWAY IN PC12 CELLS: 1.5
SIGNAL TRANSDUCTION DOWNSTREAM SIGNAL TRANSDUCTION: 1
SUFU DN: 0.96
T1 TARGETS: 0.66
B2 CDC25A HOMORIGENESIS BY ERBB2 CDC25A HOMORIGENESIS BY ERBB2 CDC25A: 0.67
3 ANDAN INVERSED TARGETS OF TP53 ANDAN INVERSED TARGETS OF TP53 AND TP73: 0.83
F INCIPITANOCK ALZHEIMERS DISEASE INCIPITANOCK ALZHEIMERS DISEASE INCIPITANT: 0.33
NOSIONS: G12CURONATE INTERCONVERSIONS: 0.33
RS DISEASE: 1.3
1 ANDZHEAN MULTIPLE MYELOMA CD1 ANDZHEAN MULTIPLE MYELOMA CD1 AND CD2: 0.33
1 TARGETS: 0.27
SE AND XPC: 0.51
AST_CANCER: 0.15





Class:SHHa Sample:MD_113 Prob(SHHa) = 1


Class:SHHb Sample:MD_113 Prob(SHHb) = 2.38e-

Class:SHHa Sample:MD_197 Prob(SHHa) = 1



Cumulative log odds: 340



Cumulative log odds: -340



Cumulative log odds: 330




Class:SHHb Sample:MD_197 Prob(SHHb) = 4.59e-



Class:SHHa Sample:MD_186 Prob(SHHa) = 2.17e-

Class:SHHb Sample:MD_186 Prob(SHHb) = 1


Cumulative log odds: -330



Cumulative log odds: -120



Cumulative log odds: 120




Class:SHHa Sample:MD_7.1 Prob(SHHa) = 1

Class:SHHb Sample:MD_7.1 Prob(SHHb) = 1.29e-


Class:SHHa Sample:MD_183 Prob(SHHa) = 1

Relative log odds: 430


KR_PATHWAY: -2.3
NG_PATHWAY: -2.3
AQUAPORIN: -2.3
CK1_PATHWAY: -2.3
ALAMUS_DN: -2.3
MEMBRANE: -2.3
PC12_DIFFERENTIATION: -2.3
ANSOMETION: -2.3
SUFU_DN: -2.3
TUT1_TARGETS: -2.3
ERBB2_CDC25A_TUMORIGENESIS: -2.3
SKIN_TNFRS2D_TARGETS: -2.3
INCIPITNOC7ALZHEIM: -2.3
INTERCONVERSIONS: -2.3
S_DISEASE: -2.3
AND_XPC: -2.3
AST_CANCER: -2.3



Evidence (posterior log odds)



Evidence (posterior log odds)




Class:SHHb Sample:MD_183 Prob(SHHb) = 6.82e-

Class:SHHa Sample:MD_58 Prob(SHHa) = 1


Class:SHHb Sample:MD_58 Prob(SHHb) = 5.63e-

Relative log odds: -290


KR_PATHWAY: 0.92
G_PATHWAY: 0.92
AQUAPORIN: 0.92
CK1_PATHWAY: 0.92
ALAMUS_DN: 0.92
MEMBRANE: 0.92
PC12_DIFFERENTIATION: 0.92
ANSOMETION: 0.92
SUFU_DN: 0.92
TUT1_TARGETS: 0.92
ERBB2_CDC25A_TUMORIGENESIS: 0.92
SKIN_TNFRS2D_TARGETS: 0.92
INCIPITNOC7ALZHEIM: 0.92
INTERCONVERSIONS: 0.92
S_DISEASE: 0.92
AND_XPC: 0.92
AST_CANCER: 0.92



Evidence (posterior log odds)



Evidence (posterior log odds)



Class:SHHb Sample:MD_147 Prob(SHHb) = 1.4e-

